Nasdaq
$10.58▲ 0.09%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.78BShares out 1.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 10.14Pre-market26.10.14 21:358-KKey event#●●●#●●●#●●●
Vir Biotechnology, Inc.Bullish
Vir Biotechnology has entered into a strategic collaboration and license agreement with Gilead Sciences to develop three novel PRO-XTEN dual-masked T-cell engager (TCE) candidates for solid tumors. Vir is eligible to receive up to $135 million in upfront and near-term preclinical milestones, including a $25 million equity investment at $14.16 per share, with potential for an additional $1.74 billion in future milestones and royalties. This partnership leverages Vir's proprietary TCE discovery platform and Gilead's oncology expertise.…more
$10.58+0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.8Pre-market26.10.08 21:388-KKey event
Vir Biotechnology, Inc.
Vir Biotechnology announced that the U.S. FDA has granted Fast Track designation to its investigational prostate cancer therapy, VIR-5500. This designation is expected to expedite the development and review process, as the company prepares to initiate pivotal Phase 3 trials in 2027 in collaboration with Astellas Pharma.…more
$10.58+0.09%vs prev closeView filingShare - 10.6Regular26.10.07 03:143Ownership
Vir Biotechnology, Inc.
Aziz Sawaf, an insider at Vir Biotechnology, has filed a power of attorney to authorize designated agents to handle SEC reporting requirements. This filing formalizes the delegation of authority for submitting Form 3, 4, 5, and Form 144 filings under Section 16 of the Exchange Act.…more
$10.58+0.09%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Regular26.10.15 01:58#●●●#●●●
Vir Biotechnology and Gilead Partner for Solid Tumor Therapies
Vir Biotechnology has entered a collaboration with Gilead Sciences to develop three novel T-cell engagers for the treatment of solid tumors. Under the deal, Vir will receive upfront payments and equity investment, with potential milestone payments reaching up to $1.74 billion.…more
$10.58+0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.14Pre-market26.10.14 21:34
●●●●●●●● ●●●●● ●●●●●●
Vir Biotechnology has entered into a collaboration and license agreement with Gilead to develop three novel T-cell engager candidates for solid tumors. The deal provides Vir with up to $135 million in upfront and near-term preclinical milestone payments.…more
$10.58+0.09%vs prev closeShareBenzinga - 10.8Pre-market26.10.08 21:33
●●●●●●●● ●●●●● ●●●●●●
Vir Biotechnology's VIR-5500 has been granted FDA Fast Track designation for the treatment of metastatic castration-resistant prostate cancer. The candidate is being co-developed with Astellas Pharma as part of a global strategic collaboration.…more
$10.58+0.09%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report